Bausch Health and Glenmark receive Health Canada approval for RYALTRIS

27 Sep 2022 , 01:33 AM

Bausch Health Companies Inc Bausch Health and Glenmark Specialty SA a subsidiary of Glenmark Pharmaceuticals Glenmark announced that RYALTRIS olopatadine hydrochloride and mometasone furoate nasal spray has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis SAR and associated ocular symptoms in adults adolescents and children aged 6 years and older RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR both nasal and ocular in one easy-to-use nasal spray The onset of action for nasal symptom relief occurs within 15 minutes after administration of RYALTRIS